Adalimumab-Adaz Injection shortage
Adalimumab-Adaz Injection is currently listed in shortage by the FDA. The FDA lists 5 affected products. This page was last refreshed from FDA data on Sep 25, 2026.
Sandoz is stopping Adalimumab-Adaz injection, and this change may be permanent. Sandoz notes that an equivalent Sandoz format is available, and matching strengths are also listed by other manufacturers not reporting a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Adalimumab-Adaz Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jan 13, 2026Currently in shortage5 of 5 products affected.
-
Jan 13, 2026First reported to the FDA5 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Sandoz Inc. 📞 800-525-8747 5 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) | — | — | Equivalent Sandoz format is available. | — |
| To Be Discontinued | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) | — | — | Equivalent Sandoz format is available. | — |
| To Be Discontinued | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) | — | — | Equivalent Sandoz format is available. | — |
| To Be Discontinued | Hyrimoz, Injection, Kit (NDC 61314-517-36) | — | — | Equivalent Sandoz format is available. | — |
| To Be Discontinued | Hyrimoz, Injection, Kit (NDC 61314-531-64) | — | — | Equivalent Sandoz format is available. | — |
These rows are manufacturer reports to the FDA for Adalimumab-Adaz Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Adalimumab-Adaz Injection? options further down this page.
Why is Adalimumab-Adaz Injection in shortage?
Sandoz has reported to the FDA that several specific package configurations of Hyrimoz (adalimumab-adaz) are being permanently discontinued. This affects the 80 mg/0.8 mL vials (in two different package sizes), the 40 mg/0.4 mL vials, and two kit configurations. Sandoz did not share a specific public reason for why these particular packages are being stopped.
The good news is that for every one of these discontinued packages, Sandoz has noted that an equivalent Sandoz format is still available. So while these specific package sizes and configurations are going away, the medication itself is not disappearing from Sandoz's lineup entirely — just the way it's packaged in these particular presentations is changing.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Adalimumab-Adaz Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Adalimumab-Adaz Injection?
Adalimumab-Adaz Injection is currently on the FDA drug-shortage list, and the manufacturer has marked this product to be discontinued. Because a discontinuation may be permanent, the best next step is a conversation with your prescriber or pharmacist about how to continue your treatment.
Both strengths on this record — the 80 mg/0.8 mL and the 40 mg/0.4 mL — currently have no available source from the manufacturer who filed this report. The reported note says an equivalent Sandoz format is available, and the same medicine (adalimumab) is still listed from other makers, including additional strengths such as 20 mg/0.2 mL and 10 mg/0.1 mL. Keep in mind this report reflects only one manufacturer, so other companies may still supply this medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy whether the same medicine is available from another maker (for example, Sandoz or Cordavis products on record); it may need to be ordered and may not be in local stock.
- Since your product is being discontinued, ask your prescriber or pharmacist about a clinician-chosen option to keep your treatment on track.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Adalimumab-Adaz Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Adalimumab-Adaz Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Adalimumab | ADALIMUMAB 80 mg/.8mL | Injection, Solution · Subcutaneous | Sandoz Inc | 61314-0325-20 |
| Adalimumab | ADALIMUMAB 40 mg/.4mL | Injection, Solution · Subcutaneous | Sandoz Inc | 61314-0327-20 |
| Adalimumab | ADALIMUMAB 20 mg/.2mL | Injection, Solution · Subcutaneous | Sandoz Inc | 61314-0332-64 |
| Adalimumab | ADALIMUMAB 10 mg/.1mL | Injection, Solution · Subcutaneous | Sandoz Inc | 61314-0391-64 |
| Hyrimoz | ADALIMUMAB 40 mg/.4mL | Injection, Solution · Subcutaneous | Cordavis Limited | 83457-0100-01 |
| Hyrimoz | ADALIMUMAB 40 mg/.8mL | Injection, Solution · Subcutaneous | Cordavis Limited | 83457-0102-01 |
| Hyrimoz | ADALIMUMAB 80 mg/.8mL | Injection, Solution · Subcutaneous | Cordavis Limited | 83457-0107-01 |
| Hyrimoz | ADALIMUMAB 20 mg/.2mL | Injection, Solution · Subcutaneous | Cordavis Limited | 83457-0108-01 |
| Hyrimoz | Kit | Cordavis Limited | 83457-0112-01 |
Therapeutic equivalents & pricing 9 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Adalimumab 40 mg/.4mL | Sandoz | 2 syringes | $1,587.820 | — | Availability likely |
| Hyrimoz 40 mg/.4mL | Sandoz | 2 syringes | — | — | FDA listed |
| Hyrimoz 40 mg/.4mL | Cordavis | 2 syringes | — | — | FDA listed |
| Hyrimoz 40 mg/.4mL | Cordavis | 2 syringes | — | — | FDA listed |
| Adalimumab 80 mg/.8mL | Sandoz | 2 syringes | — | — | FDA listed |
| Hyrimoz 80 mg/.8mL | Sandoz | 3 syringes | — | — | FDA listed |
| Hyrimoz 80 mg/.8mL | Cordavis | 2 syringes | — | — | FDA listed |
| Hyrimoz 80 mg/.8mL | Cordavis | 3 syringes | — | — | FDA listed |
| Hyrimoz 80 mg/.8mL | Sandoz | 3 syringes | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Adalimumab-Adaz Injection — that fall in the same broad treatment class (anti-inflammatory tumor necrosis factor inhibitor) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other rheumatology shortages
Adalimumab-Adaz Injection shortage FAQs
Is Adalimumab-Adaz Injection in shortage?
Which products are affected?
When will Adalimumab-Adaz Injection be available again?
Can I still get Adalimumab-Adaz somewhere?
What should I do if I take Adalimumab-Adaz Injection?
Still have a question about the Adalimumab-Adaz Injection shortage?
Ask a pharmacist about this shortage →View Adalimumab-Adaz Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.